Image Place holder

Manish Kohli, MD

Vice Chair, Department of Genitourinary Oncology

Specialty: Hematology/Oncology
Program: Genitourinary Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: Prostate Cancer , Testicular Cancer , Bladder Cancer , Kidney (Renal Cell) Cancer

Dr. Kohli earned his MBBS in Medicine/Surgery at Maulana Azad Medical College, University of Delhi, India in 1990. He completed an Internal Medicine Residency at Cook County Hospital in Illinois in 1996, followed by a Hematology-Oncology Fellowship at University of Arkansas in 1999 for Medical Sciences. Dr. Kohli also completed a certification in Clinical Trials Concentration–Global Clinical Scholars Research Training Program at Harvard Medical School, Office of Global Education, Boston, Massachusetts. After completing his Fellowship, Dr. Kohli was appointed as Assistant Professor  in 1999 and Associate Professor in 2004 at the University of Arkansas for Medical Sciences in Little Rock. In 2005 he joined the University of Rochester Medical Center, Rochester, New York as Associate Professor  where he also served as the Co-Director of Inpatient Oncology Services at Strong Memorial Hospital. He later joined Mayo Clinic, Rochester in 2008 until 2018.  Dr. Kohli has been a Consultant in the Division of Medical Oncology at the Mayo Clinic, Rochester, Minnesota, with a joint appointment in the Department of Oncology and the Department of Urology and a Professor of Oncology at the Mayo Clinic College of Medicine and Science. He was also the Chair of the Medical Oncology Genitourinary group and held an Adjunct Faculty Member position at the University of Illinois at Urbana-Champaign, Omics Nanotechnology for Cancer Precision Medicine. Dr. Kohli’s clinical expertise includes all advanced stage genitourinary malignancies, with a specific focus on advanced prostate cancer. He embraces multi-disciplinary collaboration to ensure the delivery of practical, evidence-based care, particularly for patients with high-risk local-stage genitourinary malignancies. An expert on the delivery of precision medical care, Dr. Kohli is currently Co-Principal Investigator on multiple NIH R01 grant awards that are investigating cell-free nucleic acid-based biomarkers in advanced prostate cancer and the application of nano technology sciences to clinical medicine. He has also held Department of Defense synergistic IDEA development awards (SIDA) and several national foundation grant awards in prostate cancer research. Dr. Kohli’s research interests aim to fuse the power of tumor genomics with emerging sciences such as nanotechnology, using biomarkers to determine the most effective treatment strategy, from standard-of-care drugs to promising therapies being investigated in clinical trials. He holds multiple patents, enabling prediction of responses to androgen deprivation therapy and providing algorithmic approach for determining the plasma and urine genome abnormality scores based on cell-free DNA copy number variation in advanced genitourinary cancers.

Education & Training

Fellowship:

  • University of Arkansas - Hematology/Oncology

Residency:

  • Cook County Hospital - Internal Medicine
Participating Trials

CLINICAL TRIAL 19137
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
Condition: Genitourinary
Intervention: Abiraterone acetate; Olaparib (Lynparza); Zytiga (Abiraterone acetate); prednisone
Open

CLINICAL TRIAL 19988
A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Condition: Genitourinary
Intervention: IMMU-132
Open

CLINICAL TRIAL 19435
Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); Casodex (Bicalutamide); Lupron (leuprolide acetate); Nivolumab
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Jimenez RE, Atwell TD, Sicotte H, Eckloff B, Wang L, Barman P, Sinnwell JP, Eiken PW, McMenomy BP, Tan W, Wang L, Carlson RE, Kohli M. A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens. Mayo Clin Proc Innov Qual Outcomes. 2019 Mar;3(1):14-22. Pubmedid: 30899904. Pmcid: PMC6410334.
  • Riaz IB, Faridi W, Husnain M, Malik SU, Sipra QUAR, Gondal FR, Xie H, Yadav S, Kohli M. Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2019 Jul;94(8):1524-1534. Pubmedid: 31303430.
  • Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression. Mol Cell. 2019 Jan;73(1):22-35.e6. Pubmedid: 30527665.
  • Nhola LF, Abdelmoneim SS, Villarraga HR, Kohli M, Grothey A, Bordun KA, Cheung M, Best R, Cheung D, Huang R, Barros-Gomes S, Pitz M, Singal PK, Jassal DS, Mulvagh SL. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. J Am Soc Echocardiogr. 2019 Feb;32(2):267-276. Pubmedid: 30459123.
  • Blee AM, He Y, Yang Y, Ye Z, Yan Y, Pan Y, Ma T, Dugdale J, Kuehn E, Kohli M, Jimenez R, Chen Y, Xu W, Wang L, Huang H. Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in and -Mutated Prostate Cancer. Clin Cancer Res. 2018 Sep;24(18):4551-4565. Pubmedid: 29844131. Pmcid: PMC6139075.
  • Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. Prostate Cancer P D. 2018 Sep;21(3):411-418. Pubmedid: 29858592. Pmcid: PMC6126974.
  • Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, Costello BA, Quevedo F, Pagliaro L, Kohli M. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer P D. 2018 Sep;21(3):431-437. Pubmedid: 29858590. Pmcid: PMC6126956.
  • Smith L, Kohli M, Smith AM. Expanding the Dynamic Range of Fluorescence Assays through Single-Molecule Counting and Intensity Calibration. J Am Chem Soc. 2018 Oct;140(42):13904-13912. Pubmedid: 30215524. Pmcid: PMC6462413.
  • Riaz IB, Wang L, Kohli M. Liquid biopsy approach in the management of prostate cancer. Transl Res. 2018 Nov;201:60-70. Pubmedid: 29936077. Pmcid: PMC6631037.
  • Zhang P, Xia JH, Zhu J, Gao P, Tian YJ, Du M, Guo YC, Suleman S, Zhang Q, Kohli M, Tillmans LS, Thibodeau SN, French AJ, Cerhan JR, Wang LD, Wei GH, Wang L. High-throughput screening of prostate cancer risk loci by single nucleotide polymorphisms sequencing. Nat Commun. 2018 May;9(1):2022. Pubmedid: 29789573. Pmcid: PMC5964124.
  • Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol. 2018 Jun;73(6):847-855. Pubmedid: 29475737. Pmcid: PMC6010352.
  • Qin S, Liu D, Kohli M, Wang L, Vedell PT, Hillman DW, Niu N, Yu J, Weinshilboum RM, Wang L. TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. Clin Pharmacol Ther. 2018 Jul;104(1):201-210. Pubmedid: 29027195. Pmcid: PMC5899062.
  • Sanhueza C, Kohli M. Clinical and Novel Biomarkers in the Management of Prostate Cancer. CURR TREAT OPTION ON. 2018 Feb;19(2):8. Pubmedid: 29423762.
  • He Y, Lu J, Ye Z, Hao S, Wang L, Kohli M, Tindall DJ, Li B, Zhu R, Wang L, Huang H. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. Nucleic Acids Res. 2018 Feb;46(4):1895-1911. Pubmedid: 29309643. Pmcid: PMC5829742.
  • Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 Feb;36(4):376-382. Pubmedid: 29261442. Pmcid: PMC5805480.
  • Yang Y, Bai Y, He Y, Zhao Y, Chen J, Ma L, Pan Y, Hinten M, Zhang J, Karnes RJ, Kohli M, Westendorf JJ, Li B, Zhu R, Huang H, Xu W. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2018 Feb;24(4):834-846. Pubmedid: 29167276. Pmcid: PMC5816982.
  • Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol. 2018 Feb;29(2):352-360. Pubmedid: 29069303.
  • Du M, Giridhar KV, Tian Y, Tschannen MR, Zhu J, Huang CC, Kilari D, Kohli M, Wang L. Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. Oncotarget. 2017 Sep;8(38):63703-63714. Pubmedid: 28969022. Pmcid: PMC5609954.
  • Giridhar KV, Kohli M. Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer. Mayo Clin Proc. 2017 Oct;92(10):1564-1582. Pubmedid: 28982487.
  • Giridhar KV, Sosa CP, Hillman DW, Sanhueza C, Dalpiaz CL, Costello BA, Quevedo FJ, Pitot HC, Dronca RS, Ertz D, Cheville JC, Donkena KV, Kohli M. Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma. Int J Mol Sci. 2017 Nov;18(11). Pubmedid: 29099775. Pmcid: PMC5713295.
  • Zhang BY, Riska SM, Mahoney DW, Costello BA, Kohli R, Quevedo JF, Cerhan JR, Kohli M. Germline genetic variation in JAK2 as a prognostic marker in castration-resistant prostate cancer. BJU Int. 2017 Mar;119(3):489-495. Pubmedid: 27410686.
  • Shenoy N, Dronca R, Quevedo F, Boorjian SA, Cheville J, Costello B, Kohli M, Witzig T, Pagliaro L. Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity?. Chin J Cancer Res. 2017 Aug;29(4):374-378. Pubmedid: 28947870. Pmcid: PMC5592826.
  • Kohli M, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, Thai H, Jimenez R, Huang H, Vedell PT, Eckloff BW, Quevedo JF, Pitot HC, Costello BA, Jen J, Wieben ED, Silverstein KAT, Lang JM, Wang L, Dehm SM. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. Clin Cancer Res. 2017 Aug;23(16):4704-4715. Pubmedid: 28473535. Pmcid: PMC5644285.
  • Shenoy N, Kohli M. Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer. Indian J Urol. 2016 Oct;32(4):257-261. Pubmedid: 27843206. Pmcid: PMC5054654.
  • Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, Carlson R, Rangel L, Reagan K, Davis BJ, Karnes RJ, Kohli M, Tindall D, Klein EA, Sharifi N. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol. 2016 Oct;17(10):1435-1444. Pubmedid: 27575027. Pmcid: PMC5135009.
  • Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, You M, Wang L. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer. 2016 Nov;15(1):70. Pubmedid: 27832783. Pmcid: PMC5105253.
  • Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol. 2016 May;34(13):1500-1509. Pubmedid: 26926681.
  • Zhao J, Zhao Y, Wang L, Zhang J, Karnes RJ, Kohli M, Wang G, Huang H. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer. Oncotarget. 2016 Jun;7(25):38551-38565. Pubmedid: 27221037. Pmcid: PMC5122410.
  • Xia Y, Huang CC, Dittmar R, Du M, Wang Y, Liu H, Shenoy N, Wang L, Kohli M. Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget. 2016 Jun;7(24):35818-35831. Pubmedid: 27127882. Pmcid: PMC5094965.
  • Binder M, Zhang BY, Hillman DW, Kohli R, Kohli T, Lee A, Kohli M. Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. Int J Mol Sci. 2016 Jul;17(7). Pubmedid: 27409606. Pmcid: PMC4964473.
  • Yuan T, Huang X, Woodcock M, Du M, Dittmar R, Wang Y, Tsai S, Kohli M, Boardman L, Patel T, Wang L. Plasma extracellular RNA profiles in healthy and cancer patients. Sci Rep. 2016 Jan;6:19413. Pubmedid: 26786760. Pmcid: PMC4726401.
  • Elishmereni M, Kheifetz Y, Shukrun I, Bevan GH, Nandy D, McKenzie KM, Kohli M, Agur Z. Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data. Prostate. 2016 Jan;76(1):48-57. Pubmedid: 26419619.
  • Wang L, Nie J, Sicotte H, Li Y, Eckel-Passow JE, Dasari S, Vedell PT, Barman P, Wang L, Weinshiboum R, Jen J, Huang H, Kohli M, Kocher JP. Measure transcript integrity using RNA-seq data. BMC Bioinformatics. 2016 Feb;17:58. Pubmedid: 26842848. Pmcid: PMC4739097.
  • Hart SN, Ellingson MS, Schahl K, Vedell PT, Carlson RE, Sinnwell JP, Barman P, Sicotte H, Eckel-Passow JE, Wang L, Kalari KR, Qin R, Kruisselbrink TM, Jimenez RE, Bryce AH, Tan W, Weinshilboum R, Wang L, Kohli M. Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open. 2016 Apr;6(4):e010332. Pubmedid: 27084275. Pmcid: PMC4838679.
  • Thanarajasingam G, Milone M, Kohli M. Paraneoplastic encephalopathy: an unusual presenting feature of bladder cancer metastasis. BMJ Case Rep. 2015 May;2015. Pubmedid: 25939973. Pmcid: PMC4434336.
  • Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, Yuan T, Guo Y, Wang Y, Tschannen MR, Worthey E, Jacob H, See W, Kilari D, Wang X, Hovey RL, Huang CC, Wang L. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget. 2015 Jun;6(18):16411-16421. Pubmedid: 25915538. Pmcid: PMC4599278.
  • Kohli M, Young CY, Tindall DJ, Nandy D, McKenzie KM, Bevan GH, Donkena KV. Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer. Onco Targets Ther. 2015 Jul;8:1915-1922. Pubmedid: 26261420. Pmcid: PMC4527520.
  • Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015 Jan;67(1):33-41. Pubmedid: 25129854. Pmcid: PMC4252606.
  • Kohli M, Wang L, Xie F, Sicotte H, Yin P, Dehm SM, Hart SN, Vedell PT, Barman P, Qin R, Mahoney DW, Carlson RE, Eckel-Passow JE, Atwell TD, Eiken PW, McMenomy BP, Wieben ED, Jha G, Jimenez RE, Weinshilboum R, Wang L. Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. PLoS One. 2015 Dec;10(12):e0145176. Pubmedid: 26695660. Pmcid: PMC4687867.
  • Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug;373(8):737-746. Pubmedid: 26244877. Pmcid: PMC4562797.
  • Bordun KA, Premecz S, daSilva M, Mandal S, Goyal V, Glavinovic T, Cheung M, Cheung D, White CW, Chaudhary R, Freed DH, Villarraga HR, Herrmann J, Kohli M, Ravandi A, Thliveris J, Pitz M, Singal PK, Mulvagh S, Jassal DS. The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015 Aug;309(4):H692-H701. Pubmedid: 26092985.
  • Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014 Sep;89(9):1287-1306. Pubmedid: 25192616. Pmcid: PMC4258909.
  • Loprinzi PD, Kohli M. Health characteristics and sedentary behavior impact on prostate-specific antigen levels in a national U.S. sample. J Phys Act Health. 2014 Nov;11(8):1587-1592. Pubmedid: 24384552.
  • Wu Q, Kohli M, Bergen HR, Cheville JC, Karnes RJ, Cao H, Young CY, Tindall DJ, McNiven MA, Donkena KV. Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther. 2014 May;13(5):1067-1077. Pubmedid: 24674886. Pmcid: PMC4308972.
  • Yuan T, Huang X, Dittmar RL, Du M, Kohli M, Boardman L, Thibodeau SN, Wang L. eRNA: a graphic user interface-based tool optimized for large data analysis from high-throughput RNA sequencing. BMC Genomics. 2014 Mar;15:176. Pubmedid: 24593312. Pmcid: PMC4029068.
  • Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014 Mar;120(5):692-701. Pubmedid: 24249435.
  • Vaa B, Kohli M, Price KA, Swetz KM. Solitary cystic cerebellar metastasis in a patient with invasive transitional cell carcinoma of the bladder. BMJ Case Rep. 2014 Jun;2014. Pubmedid: 24920508. Pmcid: PMC4069751.
  • Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ. Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget. 2014 Feb;5(3):824-840. Pubmedid: 24583788. Pmcid: PMC3996656.
  • Kohli M, Loprinzi PD. Serum prostate-specific antigen association with neutrophil counts: results from the National Health and Nutrition Examination Survey 2001-2010. Int J Urol. 2014 Feb;21(2):224-225. Pubmedid: 23906321.
  • Welch BT, Callstrom MR, Morris JM, Kurup AN, Schmit GD, Weisbrod AJ, Lohse CM, Kohli M, Costello BA, Olivier KR, Thompson RH, Boorjian SA, Atwell TD. Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. J Urol. 2014 Aug;192(2):357-363. Pubmedid: 24631107.
  • Ma L, Kohli M, Smith A. Nanoparticles for combination drug therapy. ACS Nano. 2013 Nov;7(11):9518-9525. Pubmedid: 24274814. Pmcid: PMC3894659.
  • Kohli M. Does our "flight and fight" response have a link with cancer?. Mayo Clin Proc. 2013 Nov;88(11):1185-1187. Pubmedid: 24182698.
  • Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, Liang M, Dittmar RL, Liu Y, Liang M, Kohli M, Thibodeau SN, Boardman L, Wang L. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. 2013 May;14:319. Pubmedid: 23663360. Pmcid: PMC3653748.
  • Tilburt JC, Kim S, Kohli M, Nahbhan M. In reply. Mayo Clin Proc. 2013 Mar;88(3):308. Pubmedid: 23489461.
  • Loprinzi PD, Kohli M. Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003-2006. Mayo Clin Proc. 2013 Jan;88(1):11-21. Pubmedid: 23274016.
  • Zhang B, Malouf J, Young P, Kohli M, Dronca R. Cardiac Metastasis in Renal Cell Carcinoma without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease. Rare Tumors. 2013;5(3):e29. Pubmedid: 24179641. Pmcid: PMC3804804.
  • Kohli M, Qin R, Jimenez R, Dehm SM. Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012 Sep;2012:781459. Pubmedid: 22956944. Pmcid: PMC3432332.
  • Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. J Mens Health. 2012 Sep;9(3):182-189. Pubmedid: 24416090. Pmcid: PMC3886726.
  • Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA, Qin R, Lamba J, Sahasrabudhe DM, Cerhan JR. Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc. 2012 Mar;87(3):240-246. Pubmedid: 22386179. Pmcid: PMC3538410.
  • Jones JM, Kohli M, Loprinzi CL. Androgen deprivation therapy-associated vasomotor symptoms. Asian J Androl. 2012 Mar;14(2):193-197. Pubmedid: 22286861. Pmcid: PMC3338189.
  • Nabhan M, Kim SP, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC. The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc. 2012 Jun;87(6):540-547. Pubmedid: 22677074. Pmcid: PMC3498058.
  • Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV. Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells. Evid Based Complement Alternat Med. 2012 Aug;2012:303019. Pubmedid: 22461839. Pmcid: PMC3296311.
  • Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV. Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J. 2011 Sep;13(3):365-377. Pubmedid: 21560017. Pmcid: PMC3144372.
  • Kohli M, Williams K, Yao JL, Dennis RA, Huang J, Reeder J, Ricke WA. Thrombin expression in prostate: a novel finding. Cancer Invest. 2011 Jan;29(1):62-67. Pubmedid: 21166500. Pmcid: PMC3136353.
  • Block MS, Kohli M. Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib. Clin Adv Hematol Oncol. 2011 Apr;9(4):335-338. Pubmedid: 21558995.
  • Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clin Proc. 2010 Jan;85(1):77-86. Pubmedid: 20042563. Pmcid: PMC2800284.
  • Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R. Multiple urinary bladder masses from metastatic prostate adenocarcinoma. Rare Tumors. 2010 Dec;2(4):e65. Pubmedid: 21234257. Pmcid: PMC3019600.
  • Kohli M, Rothberg PG, Feng C, Messing E, Joseph J, Rao SS, Hendershot A, Sahsrabudhe D. Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark. 2010 Dec;7(2):101-108. Pubmedid: 21178268. Pmcid: PMC3982319.
  • Yao JL, Ryan CK, Francis CW, Kohli M, Taubman MB, Khorana AA. Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest. 2009 May;27(4):430-434. Pubmedid: 19219655.
  • Kaushal V, Mukunyadzi P, Siegel ER, Dennis RA, Johnson DE, Kohli M. Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):1-6. Pubmedid: 18091328.
  • Kohli M, Viswamitraa S, Schaefer R, Faas FH, Kumar U. Metastasectomy for isolated bilateral adrenal metastases in hormone-refractory prostate cancer. Clin Adv Hematol Oncol. 2006 Oct;4(10):754-755. Pubmedid: 17099632.
  • Kohli S, Kohli M. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer: are there implications for blood pressure management in patients receiving chemotherapy?. J Clin Oncol. 2006 May;24(15):2399. Pubmedid: 16710045.
  • Alikhan MA, Williams R, Udaya K, Shaefer RF, Viswamitra SC, Kohli M. Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma. Int J Urol. 2006 Jun;13(6):798-800. Pubmedid: 16834663.
  • Kohli M, Schaefer R. Management of solitary palatal metastasis from renal cell carcinoma. Nat Clin Pract Urol. 2006 Jul;3(7):392-396. Pubmedid: 16835627.
  • Kohli M. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer. 2006 Jan;106(1):234-235. Pubmedid: 16284988.
  • Kohli M, Siegel E, Bhattacharya S, Khan MA, Shah R, Suva LJ. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark. 2006 Dec;2(6):249-258. Pubmedid: 17264396.
  • Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr;98(8):516-521. Pubmedid: 16622120.
  • Alikhan M, Spencer HJ, Kohli M. High-dose interleukin-2 may not be superior to low-dose interleukin-2 plus interferon. J Clin Oncol. 2005 Sep;23(25):6267-6268. Pubmedid: 16135500.
  • Challagundla S, Gokden M, Viswamitra S, Kohli M. Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage. Clin Prostate Cancer. 2005 Sep;4(2):134-137. Pubmedid: 16197616.
  • Midathada M, Safar A, Schaefer R, Viswamitra S, Kohli M. Ocular melanoma versus ocular metastasis: a diagnostic dilemma. Clin Adv Hematol Oncol. 2005 May;3(5):425-427. Pubmedid: 16167017.
  • Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct;351(15):1513-1520. Pubmedid: 15470214.
  • Kohli M, Zent C, Hutchins LF, Safar M, Dotson P, Mehta P. The academic hematology-oncology firm:a model for postgraduate cancer education. J Cancer Educ. 2004 Mar;19(1):45-49. Pubmedid: 15059755.
  • Alikhan MA, Phooskooru V, Kohli M. Re: Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst. 2004 Dec;96(23):1794. Pubmedid: 15572762.
  • Kohli M, Kaushal V, Mehta P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Hemost. 2003 Jun;29(3):301-308. Pubmedid: 12888934.
  • Kohli M, Khan MA, Mehta P, Hutchins L. Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management?. J Clin Oncol. 2003 Jun;21(12):2445. Pubmedid: 12805351.
  • Kaushal V, Kohli M, Mehta P, Mehta JL. Potential anticancer effects of statins: fact or fiction?. Endothelium. 2003 Jan;10(1):49-58. Pubmedid: 12699077.
  • Kohli M, Kaushal V, Spencer HJ, Mehta P. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. Urology. 2003 Apr;61(4):765-769. Pubmedid: 12670562.
  • Kaushal V, Kohli M, Zangari M, Fink L, Mehta P. Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol. 2002 Jul;20(13):3042. Pubmedid: 12089240.
  • Kohli M, Fink LM, Spencer HJ, Zent CS. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis. 2002 Jan;13(1):1-5. Pubmedid: 11994561.
  • Kohli M, Schichman SA, Fink L, Zent CS. Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice. South Med J. 2000 May;93(5):469-471. Pubmedid: 10832943.